BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang L, Wang D, Zhang Z, Jiang Y, Liu Y. Isoliquiritigenin alleviates diabetic symptoms via activating AMPK and inhibiting mTORC1 signaling in diet-induced diabetic mice Treating type 2 diabetes with isoliquiritigenin. Phytomedicine 2022. [DOI: 10.1016/j.phymed.2022.153950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Bai J, Zhang H, Yang Z, Li P, Liu B, Li D, Liang S, Wang Q, Li Z, Zhang J, Chen S, Hou G, Li Y. On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide. Journal of Controlled Release 2022;352:673-684. [DOI: 10.1016/j.jconrel.2022.10.039] [Reference Citation Analysis]
2 Xiao M, Jia X, Wang N, Kang J, Hu X, Goff HD, Cui SW, Ding H, Guo Q. Therapeutic potential of non-starch polysaccharides on type 2 diabetes: from hypoglycemic mechanism to clinical trials. Crit Rev Food Sci Nutr 2022;:1-34. [PMID: 36036965 DOI: 10.1080/10408398.2022.2113366] [Reference Citation Analysis]
3 Lee CH, Tsai HY, Chen CL, Chen JL, Lu CC, Fang YP, Wu DC, Huang YB, Lin MW. Isoliquiritigenin Inhibits Gastric Cancer Stemness, Modulates Tumor Microenvironment, and Suppresses Tumor Growth through Glucose-Regulated Protein 78 Downregulation. Biomedicines 2022;10:1350. [PMID: 35740372 DOI: 10.3390/biomedicines10061350] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]